November 13, 2013- By Steven E. Greer, MD
The AHA released the long-awaited new guidelines that recommend which patients should be on a cholesterol-lowering statin, such as Lipitor or Crestor. The panel of experts incorporated evidence-based medicine into the guidelines, perhaps better than any other medical society guideline panel has done previously. However, the panel also used some very dubious statistical tools as well.
According to Read more »
Interviewed by Steven E. Greer, MD
David P. Winchester MD, Medical Director of Cancer Programs for the American College of Surgeons, discusses recent data showing a more than a 100% increase in the rate that young women with early Read more »
March 23, 2014- interviewed by Steven E. Greer, MD
With catheter based methods for replacing the aorta valve not being adopted as expected, the medical device industry is now looking to the mitral valve for hope. Doctors in London and Canada performed Read more »
October 23, 2013- Interviewed by Steven E. Greer, MD
The Healthcare Channel interviewed the CEO of MannKind, Al Mann, and the CFO, Matt Pfeffer. Topics discussed include the latest clinical trial data on inhaled insulin Afrezza and the cash situation. We also discuss Mr. Mann’s other company, Second Sight, which has a Medicare and FDA-approved bionic eye to treat diseases that damage the nerves in the retina.
Super rapid acting insulin and inhaled insulin
March 23, 2015- Interviewed by Steven E. Greer, MD
We interviewed the Principal Investigator of the PROMISE trial, Pamela Douglas, MD from Duke. Read more »
March 7, 2015- By Steven E. Greer, MD
The coffee industry has been funding mounds of junk science that purport to show the health benefits of drinking coffee, when in fact, coffee is very unhealthy to heart, brain, and blood vessels because Read more »
Update January 13, 2015- Yet another study was published highlighting the risks of daily aspirin. Read more »
Interviewed by Steven E. Greer, MD
March 19, 2013
The upcoming ASCO meeting will be dominated by numerous presentations relating to new cancer drugs targeting the cell surface molecule called PD-L1, and the immune cell receptors PD1. Early Phase 1 data in non-small cell lung cancer, renal cancer, and melanoma demonstrated such impressive sustained tumor responses that they papers were published in the New England Journal of Medicine. Antoni Ribas, MD of the UCLA Jonsson Comprehensive Cancer Center is involved in trials testing some of these new molecules. In the video interview, he explains the mechanisms of action, reviews data published so far, and previews new data to be seen at ASCO.
February 23, 2010- By Steven E. Greer, MD
Many in the cardiology community are a bit confused as to why Dr. Steven Nissen Read more »
By Steven Greer, MD
The CardioMEMS’ heart failure pressure measurement system will be evaluated by Read more »
Cardiology, Cedars Sinai LA, Late Breaking Data, Policy | apples49 | 
August 16, 2015 11:52 am | 
Comments (0) 
